COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist27/10/2025
-   
  Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-202627/10/2025
-   
  Medera Announces First Patient Dosed in Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial Evaluating SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction27/10/2025
-   
  Apyx Medical Corporation to Participate in Upcoming November Investor Conferences27/10/2025
-   
  Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches27/10/2025
-   
  OXB to participate in upcoming investor conferences and events27/10/2025
-   
  Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer27/10/2025
-   
  Inspire Medical Systems, Inc. to Present at the 2025 UBS Global Healthcare Conference27/10/2025
-   
  Simbryo Technologies Introduces Personalized Assay to Help IVF Patients Avoid Repeated Failed Transfers27/10/2025
-   
  Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®27/10/2025
-   
  Creative Medical Technology Holdings Issues Letter to Shareholders27/10/2025
-   
  Tria Federal Joins ServiceNow Partner Program to Power Digital Transformation in Government27/10/2025
-   
  KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia27/10/2025
-   
  RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET27/10/2025
-   
  Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma27/10/2025
-   
  Xenon to Report Q3 2025 Financial Results on November 3, 202527/10/2025
-   
  Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development27/10/2025
-   
  Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing27/10/2025
-   
  Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®27/10/2025
Pages